ID THOC1_HUMAN Reviewed; 657 AA. AC Q96FV9; B2RBP6; Q15219; Q64I72; Q64I73; DT 10-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 13-SEP-2023, entry version 187. DE RecName: Full=THO complex subunit 1; DE Short=Tho1; DE AltName: Full=Nuclear matrix protein p84; DE Short=p84N5; DE AltName: Full=hTREX84; GN Name=THOC1; Synonyms=HPR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND RP INTERACTION WITH RB1. RC TISSUE=Lymphocyte; RX PubMed=7525595; DOI=10.1083/jcb.127.3.609; RA Durfee T., Mancini M.A., Jones D., Elledge S.J., Lee W.H.; RT "The amino-terminal region of the retinoblastoma gene product binds a novel RT nuclear matrix protein that co-localizes to centers for RNA processing."; RL J. Cell Biol. 127:609-622(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF 1-86 RP (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=15358532; DOI=10.1016/j.febslet.2004.07.074; RA Gasparri F., Sola F., Locatelli G., Muzio M.; RT "The death domain protein p84N5, but not the short isoform p84N5s, is cell RT cycle-regulated and shuttles between the nucleus and the cytoplasm."; RL FEBS Lett. 574:13-19(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16177791; DOI=10.1038/nature03983; RA Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D., RA Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., RA Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J., RA Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L., RA Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., RA Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., RA Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K., RA Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R., RA Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.; RT "DNA sequence and analysis of human chromosome 18."; RL Nature 437:551-555(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Bone marrow; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, PTM, DOMAIN, AND MUTAGENESIS OF LEU-617 AND TRP-620. RX PubMed=10512864; DOI=10.1091/mbc.10.10.3251; RA Doostzadeh-Cizeron J., Evans R., Yin S., Goodrich D.W.; RT "Apoptosis induced by the nuclear death domain protein p84N5 is inhibited RT by association with Rb protein."; RL Mol. Biol. Cell 10:3251-3261(1999). RN [8] RP FUNCTION. RX PubMed=10840029; DOI=10.1074/jbc.m000793200; RA Doostzadeh-Cizeron J., Yin S., Goodrich D.W.; RT "Apoptosis induced by the nuclear death domain protein p84N5 is associated RT with caspase-6 and NF-kappa B activation."; RL J. Biol. Chem. 275:25336-25341(2000). RN [9] RP FUNCTION. RX PubMed=11050087; DOI=10.1074/jbc.m006944200; RA Doostzadeh-Cizeron J., Terry N.H., Goodrich D.W.; RT "The nuclear death domain protein p84N5 activates a G2/M cell cycle RT checkpoint prior to the onset of apoptosis."; RL J. Biol. Chem. 276:1127-1132(2001). RN [10] RP FUNCTION, AND INTERACTION WITH THE TREX COMPLEX. RX PubMed=11979277; DOI=10.1038/nature746; RA Straesser K., Masuda S., Mason P., Pfannstiel J., Oppizzi M., RA Rodriguez-Navarro S., Rondon A.G., Aguilera A., Struhl K., Reed R., RA Hurt E.; RT "TREX is a conserved complex coupling transcription with messenger RNA RT export."; RL Nature 417:304-308(2002). RN [11] RP SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL. RX PubMed=12096345; DOI=10.1038/sj.onc.1205583; RA Evans R.L., Poe B.S., Goodrich D.W.; RT "Nuclear localization is required for induction of apoptotic cell death by RT the Rb-associated p84N5 death domain protein."; RL Oncogene 21:4691-4695(2002). RN [12] RP IDENTIFICATION IN THE TREX COMPLEX, FUNCTION OF THE TREX COMPLEX, RP IDENTIFICATION BY MASS SPECTROMETRY, AND TISSUE SPECIFICITY. RX PubMed=15833825; DOI=10.1158/0008-5472.can-04-3624; RA Guo S., Hakimi M.A., Baillat D., Chen X., Farber M.J., Klein-Szanto A.J., RA Cooch N.S., Godwin A.K., Shiekhattar R.; RT "Linking transcriptional elongation and messenger RNA export to metastatic RT breast cancers."; RL Cancer Res. 65:3011-3016(2005). RN [13] RP IDENTIFICATION IN THE THO AND TREX COMPLEX, FUNCTION OF THE TREX COMPLEX, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=15998806; DOI=10.1101/gad.1302205; RA Masuda S., Das R., Cheng H., Hurt E., Dorman N., Reed R.; RT "Recruitment of the human TREX complex to mRNA during splicing."; RL Genes Dev. 19:1512-1517(2005). RN [14] RP FUNCTION, AND INTERACTION WITH THOC2; DDX39B AND RNA POLYMERASE II. RX PubMed=15870275; DOI=10.1128/mcb.25.10.4023-4033.2005; RA Li Y., Wang X., Zhang X., Goodrich D.W.; RT "Human hHpr1/p84/Thoc1 regulates transcriptional elongation and physically RT links RNA polymerase II and RNA processing factors."; RL Mol. Cell. Biol. 25:4023-4033(2005). RN [15] RP FUNCTION OF THE TREX COMPLEX. RX PubMed=17190602; DOI=10.1016/j.cell.2006.10.044; RA Cheng H., Dufu K., Lee C.-S., Hsu J.L., Dias A., Reed R.; RT "Human mRNA export machinery recruited to the 5' end of mRNA."; RL Cell 127:1389-1400(2006). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [17] RP FUNCTION OF THE TREX COMPLEX. RX PubMed=18974867; DOI=10.1371/journal.ppat.1000194; RA Boyne J.R., Colgan K.J., Whitehouse A.; RT "Recruitment of the complete hTREX complex is required for Kaposi's RT sarcoma-associated herpesvirus intronless mRNA nuclear export and virus RT replication."; RL PLoS Pathog. 4:E1000194-E1000194(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [19] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-133 AND LYS-300, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-2 AND SER-560, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP FUNCTION. RX PubMed=22144908; DOI=10.1371/journal.pgen.1002386; RA Dominguez-Sanchez M.S., Barroso S., Gomez-Gonzalez B., Luna R., RA Aguilera A.; RT "Genome instability and transcription elongation impairment in human cells RT depleted of THO/TREX."; RL PLoS Genet. 7:E1002386-E1002386(2011). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-4; SER-537; THR-542 RP AND SER-560, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [24] RP FUNCTION. RX PubMed=23222130; DOI=10.1093/nar/gks1188; RA Chi B., Wang Q., Wu G., Tan M., Wang L., Shi M., Chang X., Cheng H.; RT "Aly and THO are required for assembly of the human TREX complex and RT association of TREX components with the spliced mRNA."; RL Nucleic Acids Res. 41:1294-1306(2013). RN [25] RP UBIQUITINATION BY NEDD4. RX PubMed=23460917; DOI=10.1371/journal.pone.0057995; RA Song F., Fan C., Wang X., Goodrich D.W.; RT "The Thoc1 encoded ribonucleoprotein is a substrate for the NEDD4-1 E3 RT ubiquitin protein ligase."; RL PLoS ONE 8:E57995-E57995(2013). RN [26] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-31; LYS-408 AND LYS-595, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [27] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-595, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25114211; DOI=10.1073/pnas.1413825111; RA Impens F., Radoshevich L., Cossart P., Ribet D.; RT "Mapping of SUMO sites and analysis of SUMOylation changes induced by RT external stimuli."; RL Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014). RN [28] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-31, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [29] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-595, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [30] RP INTERACTION WITH LUZP4. RX PubMed=25662211; DOI=10.1093/nar/gkv070; RA Viphakone N., Cumberbatch M.G., Livingstone M.J., Heath P.R., Dickman M.J., RA Catto J.W., Wilson S.A.; RT "Luzp4 defines a new mRNA export pathway in cancer cells."; RL Nucleic Acids Res. 43:2353-2366(2015). RN [31] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-31; LYS-580 AND LYS-595, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [32] RP STRUCTURE BY NMR OF 561-657. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the death domain of nuclear matrix protein p84."; RL Submitted (JUL-2005) to the PDB data bank. RN [33] RP INVOLVEMENT IN DFNA86, AND VARIANT DFNA86 VAL-183. RX PubMed=32776944; DOI=10.1371/journal.pgen.1008953; RA Zhang L., Gao Y., Zhang R., Sun F., Cheng C., Qian F., Duan X., Wei G., RA Sun C., Pang X., Chen P., Chai R., Yang T., Wu H., Liu D.; RT "THOC1 deficiency leads to late-onset nonsyndromic hearing loss through RT p53-mediated hair cell apoptosis."; RL PLoS Genet. 16:e1008953-e1008953(2020). CC -!- FUNCTION: Required for efficient export of polyadenylated RNA. Acts as CC component of the THO subcomplex of the TREX complex which is thought to CC couple mRNA transcription, processing and nuclear export, and which CC specifically associates with spliced mRNA and not with unspliced pre- CC mRNA. TREX is recruited to spliced mRNAs by a transcription-independent CC mechanism, binds to mRNA upstream of the exon-junction complex (EJC) CC and is recruited in a splicing- and cap-dependent manner to a region CC near the 5' end of the mRNA where it functions in mRNA export to the CC cytoplasm via the TAP/NFX1 pathway. The TREX complex is essential for CC the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless CC mRNAs and infectious virus production. Regulates transcriptional CC elongation of a subset of genes. Involved in genome stability by CC preventing co-transcriptional R-loop formation. May play a role in hair CC cell formation, hence may be involved in hearing (By similarity). CC {ECO:0000250|UniProtKB:Q7SYB2}. CC -!- FUNCTION: Participates in an apoptotic pathway which is characterized CC by activation of caspase-6, increases in the expression of BAK1 and CC BCL2L1 and activation of NF-kappa-B. This pathway does not require CC p53/TP53, nor does the presence of p53/TP53 affect the efficiency of CC cell killing. Activates a G2/M cell cycle checkpoint prior to the onset CC of apoptosis. Apoptosis is inhibited by association with RB1. CC -!- SUBUNIT: Component of the THO complex, which is composed of THOC1, CC THOC2, THOC3, THOC5, THOC6 and THOC7; together with at least CC ALYREF/THOC4, DDX39B, SARNP/CIP29 and CHTOP, THO forms the CC transcription/export (TREX) complex which seems to have a dynamic CC structure involving ATP-dependent remodeling. Binds to the CC hypophosphorylated form of RB1. Interacts with THOC2, DDX39B and RNA CC polymerase II. Interacts with THOC5 (By similarity). Interacts with CC LUZP4. {ECO:0000250|UniProtKB:Q8R3N6, ECO:0000269|PubMed:11979277, CC ECO:0000269|PubMed:15833825, ECO:0000269|PubMed:15870275, CC ECO:0000269|PubMed:15998806, ECO:0000269|PubMed:25662211, CC ECO:0000269|PubMed:7525595}. CC -!- INTERACTION: CC Q96FV9; O95994: AGR2; NbExp=3; IntAct=EBI-1765605, EBI-712648; CC Q96FV9; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-1765605, EBI-11745576; CC Q96FV9; Q6PI77: BHLHB9; NbExp=3; IntAct=EBI-1765605, EBI-11519926; CC Q96FV9; P78358: CTAG1B; NbExp=3; IntAct=EBI-1765605, EBI-1188472; CC Q96FV9; O00471: EXOC5; NbExp=3; IntAct=EBI-1765605, EBI-949824; CC Q96FV9; O15481: MAGEB4; NbExp=3; IntAct=EBI-1765605, EBI-751857; CC Q96FV9; Q96BY2: MOAP1; NbExp=7; IntAct=EBI-1765605, EBI-739825; CC Q96FV9; P26367: PAX6; NbExp=3; IntAct=EBI-1765605, EBI-747278; CC Q96FV9; Q9BZL4: PPP1R12C; NbExp=3; IntAct=EBI-1765605, EBI-721802; CC Q96FV9; Q9UJ41: RABGEF1; NbExp=3; IntAct=EBI-1765605, EBI-913954; CC Q96FV9; Q04864-2: REL; NbExp=3; IntAct=EBI-1765605, EBI-10829018; CC Q96FV9; O75478: TADA2A; NbExp=3; IntAct=EBI-1765605, EBI-742268; CC Q96FV9; Q13769: THOC5; NbExp=10; IntAct=EBI-1765605, EBI-5280316; CC Q96FV9; P14373: TRIM27; NbExp=3; IntAct=EBI-1765605, EBI-719493; CC Q96FV9; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-1765605, EBI-2130429; CC Q96FV9; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-1765605, EBI-739895; CC Q96FV9; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-1765605, EBI-12030590; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus speckle. Nucleus, CC nucleoplasm. Nucleus matrix. Cytoplasm. Note=Can shuttle between the CC nucleus and cytoplasm. Nuclear localization is required for induction CC of apoptotic cell death. Translocates to the cytoplasm during the early CC phase of apoptosis execution. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96FV9-1; Sequence=Displayed; CC Name=2; Synonyms=p84N5s; CC IsoId=Q96FV9-2; Sequence=VSP_038073, VSP_038074; CC -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in various cancer cell lines. CC Expressed at very low levels in normal breast epithelial cells and CC highly expressed in breast tumors. Expression is strongly associated CC with an aggressive phenotype of breast tumors and expression correlates CC with tumor size and the metastatic state of the tumor progression. CC {ECO:0000269|PubMed:15358532, ECO:0000269|PubMed:15833825}. CC -!- INDUCTION: Up-regulated during cell proliferation. CC {ECO:0000269|PubMed:15358532}. CC -!- DOMAIN: An intact death domain is needed for apoptosis. CC {ECO:0000269|PubMed:10512864}. CC -!- PTM: Expression is altered specifically during apoptosis and is CC accompanied by the appearance of novel forms with smaller apparent CC molecular mass. CC -!- PTM: Polyubiquitinated, leading to proteasomal degradation; probably CC involves NEDD4. {ECO:0000269|PubMed:23460917}. CC -!- DISEASE: Deafness, autosomal dominant, 86 (DFNA86) [MIM:620280]: A form CC of non-syndromic, sensorineural hearing loss. Sensorineural hearing CC loss results from damage to the neural receptors of the inner ear, the CC nerve pathways to the brain, or the area of the brain that receives CC sound information. DFNA86 is characterized by progressive, bilateral CC hearing loss that is most predominant in the high frequencies, begins CC mildly during the fourth decade and gradually progresses to severe-to- CC profound deafness in the seventh and eighth decades. Affected subjects CC have tinnitus, while vestibular dysfunction or other clinical CC abnormalities are not present. {ECO:0000269|PubMed:32776944}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: [Isoform 2]: May be due to an intron retention. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36529; AAA53571.1; -; mRNA. DR EMBL; AY573302; AAT81408.1; -; mRNA. DR EMBL; AY573303; AAT81409.1; -; mRNA. DR EMBL; AK314755; BAG37293.1; -; mRNA. DR EMBL; AP000845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471113; EAX01732.1; -; Genomic_DNA. DR EMBL; BC010381; AAH10381.1; -; mRNA. DR CCDS; CCDS45820.1; -. [Q96FV9-1] DR PIR; A53545; A53545. DR RefSeq; NP_005122.2; NM_005131.2. [Q96FV9-1] DR PDB; 1WXP; NMR; -; A=561-657. DR PDB; 7APK; EM; 3.30 A; A/I/a/i=2-657. DR PDB; 7ZNK; EM; 3.90 A; A/I/a/i=1-657. DR PDB; 7ZNL; EM; 3.45 A; A/I/a/i=1-657. DR PDBsum; 1WXP; -. DR PDBsum; 7APK; -. DR PDBsum; 7ZNK; -. DR PDBsum; 7ZNL; -. DR AlphaFoldDB; Q96FV9; -. DR SMR; Q96FV9; -. DR BioGRID; 115305; 196. DR ComplexPortal; CPX-2488; TREX transcription-export complex, DX39B variant. DR ComplexPortal; CPX-7261; TREX transcription-export complex, DX39A variant. DR CORUM; Q96FV9; -. DR IntAct; Q96FV9; 91. DR MINT; Q96FV9; -. DR STRING; 9606.ENSP00000261600; -. DR TCDB; 3.A.22.1.2; the transcription-coupled trex/tap nuclear mrna export complex (trex) family. DR GlyGen; Q96FV9; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96FV9; -. DR MetOSite; Q96FV9; -. DR PhosphoSitePlus; Q96FV9; -. DR SwissPalm; Q96FV9; -. DR BioMuta; THOC1; -. DR DMDM; 37999906; -. DR EPD; Q96FV9; -. DR jPOST; Q96FV9; -. DR MassIVE; Q96FV9; -. DR MaxQB; Q96FV9; -. DR PaxDb; Q96FV9; -. DR PeptideAtlas; Q96FV9; -. DR ProteomicsDB; 76564; -. [Q96FV9-1] DR ProteomicsDB; 76565; -. [Q96FV9-2] DR Antibodypedia; 4748; 380 antibodies from 32 providers. DR DNASU; 9984; -. DR Ensembl; ENST00000261600.11; ENSP00000261600.6; ENSG00000079134.13. [Q96FV9-1] DR GeneID; 9984; -. DR KEGG; hsa:9984; -. DR MANE-Select; ENST00000261600.11; ENSP00000261600.6; NM_005131.3; NP_005122.2. DR UCSC; uc002kkj.5; human. [Q96FV9-1] DR AGR; HGNC:19070; -. DR CTD; 9984; -. DR DisGeNET; 9984; -. DR GeneCards; THOC1; -. DR HGNC; HGNC:19070; THOC1. DR HPA; ENSG00000079134; Low tissue specificity. DR MalaCards; THOC1; -. DR MIM; 606930; gene. DR MIM; 620280; phenotype. DR neXtProt; NX_Q96FV9; -. DR OpenTargets; ENSG00000079134; -. DR PharmGKB; PA134887435; -. DR VEuPathDB; HostDB:ENSG00000079134; -. DR eggNOG; KOG2491; Eukaryota. DR GeneTree; ENSGT00390000016232; -. DR HOGENOM; CLU_027906_0_0_1; -. DR InParanoid; Q96FV9; -. DR OrthoDB; 5490969at2759; -. DR PhylomeDB; Q96FV9; -. DR TreeFam; TF314796; -. DR PathwayCommons; Q96FV9; -. DR Reactome; R-HSA-159236; Transport of Mature mRNA derived from an Intron-Containing Transcript. DR Reactome; R-HSA-72187; mRNA 3'-end processing. DR Reactome; R-HSA-73856; RNA Polymerase II Transcription Termination. DR SignaLink; Q96FV9; -. DR SIGNOR; Q96FV9; -. DR BioGRID-ORCS; 9984; 703 hits in 1171 CRISPR screens. DR ChiTaRS; THOC1; human. DR EvolutionaryTrace; Q96FV9; -. DR GeneWiki; THOC1; -. DR GenomeRNAi; 9984; -. DR Pharos; Q96FV9; Tbio. DR PRO; PR:Q96FV9; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q96FV9; Protein. DR Bgee; ENSG00000079134; Expressed in calcaneal tendon and 203 other tissues. DR ExpressionAtlas; Q96FV9; baseline and differential. DR Genevisible; Q96FV9; HS. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IEA:UniProtKB-SubCell. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000347; C:THO complex; IDA:UniProtKB. DR GO; GO:0000445; C:THO complex part of transcription export complex; IDA:UniProtKB. DR GO; GO:0000346; C:transcription export complex; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0006406; P:mRNA export from nucleus; IDA:UniProtKB. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:2000002; P:negative regulation of DNA damage checkpoint; IMP:UniProtKB. DR GO; GO:0048297; P:negative regulation of isotype switching to IgA isotypes; ISS:UniProtKB. DR GO; GO:0032786; P:positive regulation of DNA-templated transcription, elongation; IMP:UniProtKB. DR GO; GO:0000018; P:regulation of DNA recombination; IMP:UniProtKB. DR GO; GO:0032784; P:regulation of DNA-templated transcription elongation; IDA:UniProtKB. DR GO; GO:0031297; P:replication fork processing; IMP:UniProtKB. DR GO; GO:0006396; P:RNA processing; TAS:ProtInc. DR GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW. DR GO; GO:0007165; P:signal transduction; IEA:InterPro. DR GO; GO:0046784; P:viral mRNA export from host cell nucleus; IDA:UniProtKB. DR CDD; cd08318; Death_NMPP84; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_domain. DR InterPro; IPR021861; THO_THOC1. DR PANTHER; PTHR13265; THO COMPLEX SUBUNIT 1; 1. DR PANTHER; PTHR13265:SF2; THO COMPLEX SUBUNIT 1; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF11957; efThoc1; 1. DR SMART; SM00005; DEATH; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR PROSITE; PS50017; DEATH_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm; KW Deafness; Disease variant; DNA-binding; Isopeptide bond; mRNA processing; KW mRNA splicing; mRNA transport; Non-syndromic deafness; Nucleus; KW Phosphoprotein; Reference proteome; RNA-binding; Transcription; KW Transcription regulation; Transport; Ubl conjugation. FT CHAIN 1..657 FT /note="THO complex subunit 1" FT /id="PRO_0000072520" FT DOMAIN 570..653 FT /note="Death" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00064" FT REGION 194..222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 533..569 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 414..430 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:12096345" FT COMPBIAS 541..555 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 4 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 133 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 300 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 542 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 560 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT CROSSLNK 31 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733" FT CROSSLNK 408 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 580 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 595 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1); alternate" FT /evidence="ECO:0007744|PubMed:25114211" FT CROSSLNK 595 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25114211, FT ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 363..377 FT /note="LLSENPPDGERFSKM -> VSSTRNKPMIEKMEI (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15358532" FT /id="VSP_038073" FT VAR_SEQ 378..657 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15358532" FT /id="VSP_038074" FT VARIANT 183 FT /note="L -> V (in DFNA86; impaired function in hair cell FT formation, when tested in a heterologous system)" FT /evidence="ECO:0000269|PubMed:32776944" FT /id="VAR_088179" FT MUTAGEN 617 FT /note="L->P: Loss of ability to induce apoptosis. FT Interferes with normal response of SaOS-2 cells to FT radiation." FT /evidence="ECO:0000269|PubMed:10512864" FT MUTAGEN 620 FT /note="W->P,R: Loss of ability to induce apoptosis. FT Interferes with normal response of SaOS-2 cells to FT radiation." FT /evidence="ECO:0000269|PubMed:10512864" FT CONFLICT 71 FT /note="N -> H (in Ref. 2; AAT81408)" FT /evidence="ECO:0000305" FT CONFLICT 86 FT /note="G -> A (in Ref. 2; AAT81408)" FT /evidence="ECO:0000305" FT CONFLICT 130 FT /note="S -> A (in Ref. 1; AAA53571)" FT /evidence="ECO:0000305" FT CONFLICT 134 FT /note="N -> S (in Ref. 3; BAG37293)" FT /evidence="ECO:0000305" FT CONFLICT 433 FT /note="M -> T (in Ref. 1; AAA53571)" FT /evidence="ECO:0000305" FT CONFLICT 480 FT /note="V -> A (in Ref. 1; AAA53571)" FT /evidence="ECO:0000305" FT CONFLICT 487 FT /note="V -> M (in Ref. 1; AAA53571)" FT /evidence="ECO:0000305" FT CONFLICT 498 FT /note="R -> K (in Ref. 1; AAA53571)" FT /evidence="ECO:0000305" FT CONFLICT 519 FT /note="P -> Q (in Ref. 1; AAA53571)" FT /evidence="ECO:0000305" FT HELIX 11..21 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 30..36 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 46..64 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 72..83 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 92..103 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 107..119 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 134..146 FT /evidence="ECO:0007829|PDB:7APK" FT STRAND 149..151 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 153..166 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 232..246 FT /evidence="ECO:0007829|PDB:7APK" FT TURN 249..252 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 255..274 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 310..313 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 315..333 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 347..365 FT /evidence="ECO:0007829|PDB:7APK" FT TURN 368..370 FT /evidence="ECO:0007829|PDB:7APK" FT HELIX 371..391 FT /evidence="ECO:0007829|PDB:7APK" FT STRAND 565..567 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 571..581 FT /evidence="ECO:0007829|PDB:1WXP" FT TURN 582..584 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 585..588 FT /evidence="ECO:0007829|PDB:1WXP" FT TURN 589..593 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 596..605 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 609..624 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 625..627 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 630..639 FT /evidence="ECO:0007829|PDB:1WXP" FT HELIX 643..650 FT /evidence="ECO:0007829|PDB:1WXP" SQ SEQUENCE 657 AA; 75666 MW; DB7980BD0F252DAB CRC64; MSPTPPLFSL PEARTRFTKS TREALNNKNI KPLLSTFSQV PGSENEKKCT LDQAFRGILE EEIINHSSCE NVLAIISLAI GGVTEGICTA STPFVLLGDV LDCLPLDQCD TIFTFVEKNV ATWKSNTFYS AGKNYLLRMC NDLLRRLSKS QNTVFCGRIQ LFLARLFPLS EKSGLNLQSQ FNLENVTVFN TNEQESTLGQ KHTEDREEGM DVEEGEMGDE EAPTTCSIPI DYNLYRKFWS LQDYFRNPVQ CYEKISWKTF LKYSEEVLAV FKSYKLDDTQ ASRKKMEELK TGGEHVYFAK FLTSEKLMDL QLSDSNFRRH ILLQYLILFQ YLKGQVKFKS SNYVLTDEQS LWIEDTTKSV YQLLSENPPD GERFSKMVEH ILNTEENWNS WKNEGCPSFV KERTSDTKPT RIIRKRTAPE DFLGKGPTKK ILMGNEELTR LWNLCPDNME ACKSETREHM PTLEEFFEEA IEQADPENMV ENEYKAVNNS NYGWRALRLL ARRSPHFFQP TNQQFKSLPE YLENMVIKLA KELPPPSEEI KTGEDEDEED NDALLKENES PDVRRDKPVT GEQIEVFANK LGEQWKILAP YLEMKDSEIR QIECDSEDMK MRAKQLLVAW QDQEGVHATP ENLINALNKS GLSDLAESLT NDNETNS //